Divi's Laboratories (DIVISLAB.NS) Aktsia Kursus
Divi's Laboratories Kursus
Viimase 19 aasta jooksul kasvas Divi's Laboratories käive 18,4 % aastas ja jõudis 93,60 B INR-ni. Kasum aktsia kohta kasvas 19,8 % aastas viimase 19 aasta jooksul. Divi's Laboratories netomarginaal 23,4 % on langenud võrreldes 28,5 %-ga mõni aasta tagasi. Tänase hinna juures on dividenditootlus umbes 0,27 %. Väljamaksesuhe on umbes 36 % kasumist. Dividend kasvas 24,0 % aastas viimase 19 aasta jooksul. Divi's Laboratories 12 kuu konsensuse hinnasiht on 7012,50 INR, umbes alla kurssi 37,3 %. 36 analüütikust 20 soovitab osta — üldine konsensus on Osta.
Divi's Laboratories aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Divi's Laboratories ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Divi's Laboratories aktsia kohta
The business model of Divi's Laboratories Ltd revolves around the manufacture and supply of active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies worldwide. With a focus on quality, innovation, and cost-effective production, Divi's Labs caters to a wide range of therapeutic segments including generics, custom synthesis, and development of new molecules. By leveraging its strong research and development capabilities, cutting-edge technology, and state-of-the-art manufacturing facilities, Divi's Labs has established itself as a trusted supplier in the global pharmaceutical industry.
Divi's Laboratories Ltd is primarily active in the pharmaceutical industry.
The main competitors of Divi's Laboratories Ltd in the market include Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, and Cipla Ltd.
Divi's Laboratories Ltd is an Indian pharmaceutical company that was founded in 1990. It is headquartered in Hyderabad, Telangana. The company specializes in the research, development, and manufacturing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Divi's Laboratories has a strong focus on quality with a global customer base and is recognized for its state-of-the-art manufacturing facilities. Over the years, the company has consistently grown and expanded its product portfolio. Divi's Laboratories is committed to innovation, research, and delivering high-quality healthcare solutions to meet the needs of patients worldwide.
Divi's Laboratories Ltd has achieved numerous significant milestones throughout its journey. Notably, the company has consistently demonstrated excellence in the pharmaceutical sector since its establishment. Divi's Laboratories Ltd has successfully garnered a strong reputation for its high-quality manufacturing practices and commitment to innovation. The company has also gained several certifications, including ISO 9001, ISO 14001, and OHSAS 18001, further solidifying its credibility. Moreover, Divi's Laboratories Ltd has expanded its operations globally, establishing a strong presence in various international markets. These incredible achievements highlight Divi's Laboratories Ltd's unwavering dedication to delivering exceptional pharmaceutical solutions while maintaining the highest standards of quality and compliance.
Divi's Laboratories Ltd is primarily present in India, with its headquarters located in Hyderabad. The company operates multiple manufacturing facilities in different locations across India, including Visakhapatnam, Hyderabad, and Mahad. Divi's Laboratories Ltd focuses on manufacturing and supplying active pharmaceutical ingredients (APIs) and intermediates globally. It has a strong presence in various countries and regions, including the United States, Europe, Japan, Korea, and several emerging markets. With its commitment to quality and adherence to international regulatory standards, Divi's Laboratories Ltd has established itself as a trusted supplier of pharmaceutical products worldwide.
Divi's Laboratories Ltd is committed to upholding values of excellence, integrity, and innovation. With a strong corporate philosophy centered around quality and customer satisfaction, the company continually strives to provide top-notch pharmaceutical products and services. Divi's Laboratories Ltd focuses on research and development to ensure cutting-edge solutions and advancements in the field. The company's emphasis on ethical practices and transparency reflects its commitment to maintaining strong relationships with stakeholders. Divi's Laboratories Ltd's dedication to continuous improvement and market leadership makes it a preferred choice for investors seeking a reliable and progressive pharmaceutical company.
Analüütikud määravad Divi's Laboratories aktsiale keskmiseks hinnasihi 6987,18 INR (mediaan: 7012,50 INR), mis on −37,5 % viimase hinna suhtes. Konsensus põhineb 36 analüütiku hinnangul.
36 analüütikut hindavad praegu Divi's Laboratories aktsiat: 21 soovitab osta, 6 hoida ja 9 müüa. 2026. aastaks ootavad analüütikud, et Divi's Laboratories teenib tulu 106,20 B INR ja kasumit aktsia kohta 97,74 INR.
Praeguse kursiga kaubeldakse Divi's Laboratories aktsiaga 109,75 EUR (11 180,50 INR) juures.
Divi's Laboratories aktsia (DIVISLAB.NS) on noteeritud 2 börsil, sh: NSE (Indien) (DIVISLAB.NS).
Divi's Laboratories Ltd is an Indian company that manufactures pharmaceutical active ingredients and intermediates for the global market. The company was founded in 1990 and is headquartered in Hyderabad, India. Divi's Laboratories' business model is based on extensive research and development and high production capacity. The company follows a vertically integrated production strategy, engaging in the development of new active ingredients and the production of intermediates and finished products. Divi's Laboratories serves a variety of industries such as the pharmaceutical and cosmetic industries, agriculture, and the food industry. The company offers a wide range of products such as antibiotics, antidepressants, vitamins, and folic acid for the pharmaceutical industry. For the cosmetic and food industries, the company offers emulsifiers, fragrances and flavors, as well as dyes and sunscreens. The company has two modern manufacturing facilities with a total capacity of over 500 tons per year. Divi's Laboratories continuously invests in state-of-the-art production facilities to increase capacity and productivity. Divi's Laboratories specializes in the manufacture of pharmaceutical active ingredients and intermediates and therefore enjoys a good reputation in the industry. The company has established a strong position in the market in recent years and has expanded into various countries such as the USA, Europe, and Asia. The company is also successful in research and development of new products. Divi's Laboratories has its own research and development department that develops new synthetic methods and processes for the production of active ingredients. The company works closely with customers to produce customized products for their specific requirements. Furthermore, Divi's Laboratories is involved in the research of natural substances that can be used in the medical field. The company has its own department for biotechnological research and development to isolate new natural substances and investigate their potential for medical application. In summary, Divi's Laboratories' business model is very successful and focused on a wide range of products and extensive research and development. The company has established a strong position in the global market for pharmaceutical active ingredients and intermediates and is on track to further expand its position.
oodatav Divi's Laboratories käive on 106,20 B INR. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Divi's Laboratories kasum on 25,92 B INR. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Divi's Laboratories jaoks on praegu 114,39. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Divi's Laboratories aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Divi's Laboratories jaoks on praegu 27,92. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Divi's Laboratories aktsia jaoks.
Eulpooli kvaliteedinäitaja Divi's Laboratories jaoks on 7/10.
Divi's Laboratories ISIN on INE361B01024. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Divi's Laboratories ticker on DIVISLAB.NS. Ticker-sümbol kasutatakse Divi's Laboratories aktsiate kauplemiseks börsil.
Divi's Laboratories aktsia
Divi's Laboratories konkurendid
Divi's Laboratories Börsiticker
Divi's Laboratories FIGI
Kõik teised näitajad ja analüüsid Divi's Laboratories kohta sügavamalt
Meie Divi's Laboratories-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Divi's Laboratories. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: